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Abstract
Background: There is limited evidence on statin risk and effectiveness for patients aged 80+. We estimated risk of recurrent myocardial 
infarction, muscle-related and other adverse events, and statin-related incremental costs in “real-world” older patients treated with statins 
versus no statins.
Methods: We used primary care electronic medical records from the UK Clinical Practice Research Datalink. Subhazard ratios (competing risk 
of death) for myocardial infarction recurrence (primary end point), falls, fractures, ischemic stroke, and dementia, and hazard ratios (Cox) for 
all-cause mortality were used to compare older (60+) statin users and 1:1 propensity-score-matched controls (n = 12,156). Participants were 
followed-up for 10 years.
Results: Mean age was 76.5 ± 9.2 years; 45.5% were women. Statins were associated with near significant reduction in myocardial infarction 
recurrence (subhazard ratio = 0.84, 0.69–1.02, p = .073), with protective effect in the 60–79 age group (0.73, 0.57–0.94) but a nonsignificant 
result in the 80+ group (1.06, 0.78–1.44; age interaction p = .094). No significant associations were found for stroke or dementia. Data suggest 
an increased risk of falls (1.36, 1.17–1.60) and fractures (1.33, 1.04–1.69) in the first 2 years of treatment, particularly in the 80+ group. 
Treatment was associated with lower all-cause mortality. Statin use was associated with health care cost savings in the 60–79 group but higher 
costs in the 80+ group.
Conclusions: Estimates of statin effectiveness for the prevention of recurrent myocardial infarction in patients aged 60–79 years were similar 
to trial results, but more evidence is needed in the older group. There may be an excess of falls and fractures in very old patients, which deserves 
further investigation.
Key Words: Statins—Myocardial infarction—Falls—Fractures—Older
Statins are cholesterol-lowering drugs commonly used to prevent 
myocardial infarction (MI), ischemic stroke [ST], and other cardio-
vascular conditions (1). Despite their widespread use in older people, 
evidence of efficacy and risks is limited for the very old and older 
people with significant comorbidities (1,2).
In the United States from 2004 to 2009, 27% of people aged 
55–79  years and 24% of those aged 80  years and older received 
statins (3). These figures are expected to rise significantly according 
to recommendations from current guidelines (1,4). Although statin 
safety and efficacy have been consistently shown in randomized 
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clinical trials (RCTs) of middle-aged and generally healthy younger 
old people (5–8), evidence in the very old and in older patients with 
greater burden of disease is poor. RCTs on statins enrolled a relatively 
low proportion of individuals aged 75 and older (1), very few patients 
with significant comorbidity, and no patient aged 85 and older (2). 
Therefore, results of available RCTs should not be extrapolated to the 
general older population and additional research is needed.
RCTs in real-world older patients are practically and ethically 
challenging, particularly for established treatments in high-risk popu-
lations; therefore, observational studies evaluating the statin risk and 
effectiveness might help clarify the risk-to-benefit ratio in this group. 
To our knowledge, only one relatively small study investigated the 
effect of statins in preventing MI recurrence in “real-world” patients 
(9). This work did not account for major confounders, explore the 
competing risk of death, or investigate concurrent adverse events (9).
Moreover, RCTs are often based on too small samples and too 
short follow-ups to provide robust evidence on adverse events. For 
this reason, the US Food and Drug Administration, for example, 
support the use of electronic medical record data to provide active 
surveillance of regulated medications (http://www.fda.gov/Safety/
FDAsSentinelInitiative/ucm149340.htm).
The present study was aimed to investigate the effectiveness of 
statins for the prevention of MI recurrence in a large sample of “typi-
cal” older patients with incident MI, accounting for many potential 
confounders and the competing risk of death. We also explored the 
risk of a number of conditions leading to disability in older age (ST, 
severe falls, fragility fractures, and dementia) and all-cause mortality, 
and estimated the effect of older age (80+) and burden of diseases on 
the association between statins and relevant end points. Finally, we 
investigated the incremental costs of statins. This was accomplished 
using a very large database of general practitioner (GP) medical 
records linked to hospital records and death certificates.
Although the presence of residual confounding from unmeasured 
factors can never be entirely excluded in observational research, 
results of this study will help increase the evidence base on statin 
risks and effectiveness in typical older people and support future 
interventional studies in this section of the population.
Methods
Data Source
We used data from the UK Clinical Practice Research Datalink 
(CPRD), a database of anonymized electronic medical records col-
lected by UK GPs (10). Only data from practices linked to Hospital 
Episode Statistics (HES; for hospital records) and Office for National 
Statistics (for health certificates) databases (10) were used. The CPRD 
has been granted Multiple Research Ethics Committee approval (05/
MRE04/87) to undertake purely observational studies, and this study 
was approved by the Independent Scientific Advisory Committee for 
MHRA database research under protocol numbers 15_192R.
Study Design and Study Sample
This is a quasi-experimental study designed as a retrospective paral-
lel-cohort study. Quasi-experiments are studies that aim to evaluate 
interventions but that do not use randomization (11). All partici-
pants were hospitalized for first MI between April 1, 1997 (first HES 
data collection) and March 31, 2014 (latest HES data collection date 
in the available data set), aged 60+ years at the time of, and alive 4 
weeks after the acute event (CONSORT diagram with participant 
selection criteria in Supplementary Figure S1).
Treatment Groups
Statins (atorvastatin, fluvastatin, pravastatin, rosuvastatin, and sim-
vastatin), regardless of strength and treatment duration, represented 
the exposure. Lovastatin (not commercialized in the UK), cerivas-
tatin (withdrawn from the market), and the association simvasta-
tin/ezetimibe were not included in the analysis. Statins were coded 
according to Chapter 2.12 of the British National Formulary (12) 
and prescriptions derived from GP records.
The treatment group included all participants never treated with 
statins before their incident MI who had records of statin prescrip-
tion within 56 days after the acute event. The control group included 
people never treated with statins before their first MI who did not 
receive a prescription of statins in the 56 days after the acute event. 
According to previous research (13), including “late” statin users in 
the control group allows both to simulate situations encountered 
during RCTs and avoid a biased comparison only with controls 
never “at risk” of being prescribed a statin. The study groups were 
followed up from the date of incident MI (baseline), until the occur-
rence of the event of interest, death, study end (ie, 10  years after 
baseline or March 31, 2014, whichever came first) or, only for “late 
statin users,” until statin prescription.
For the purpose of exploring drug persistence in people treated 
with statins, duration of treatment was assessed only in people alive 
for the entire 10-year period, as the time spanning between the first 
and the last prescription refill.
End Points
Primary end point was a composite of fatal MI (MI followed by 
death within 28 days (14)) or nonfatal MI. We used only episodes 
of MI leading to hospitalization and reported in HES records, to 
minimize misclassification given the low specificity of MI diagnosis 
in CPRD (15).
Secondary end points were ST, severe falls (requiring hospital 
admission), fragility fractures (spine, hip, wrist, humerus, pelvis, and 
ribs, requiring hospitalization), dementia, and all-cause mortality. 
These conditions were coded using ICD-10 for ST and severe falls and 
ICD-10 + OPCS-4 codes for fractures and derived from HES database. 
Dementia was coded using GP (“Read codes” adapted for CPRD) and/
or HES records (ICD-10). All-cause mortality was ascertained using a 
combination of both Office for National Statistics and GP records. 
Analyses of all secondary end points were hypothesis generating and 
excluded people with the relevant condition at baseline.
Covariates
We used a set of 73 characteristics/conditions including enrolment 
period, demographics, traditional risk factors, diseases, drugs, and 
measures of health care utilization (those included in Table  1) as 
covariates to ensure an adequate control of confounding, according 
to previous work (16). Covariates were coded by combining GP and 
HES data to reduce misclassification.
Health care costs, including statins and other medications (17), 
relevant monitoring tests (4), GP visits recorded (18), outpatient 
(18) and inpatient (19) hospital attendances were calculated based 
on GP and HES recorded events. Drugs were coded using the British 
National Formulary (12) and prescriptions derived from GP records.
Statistical Analysis
Baseline differences of both non-matched and matched samples were 
reported as mean and SD or percentages and compared using analy-
sis of variance (ANOVA) or chi-square test as appropriate.
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Table 1. Characteristics of the Matched Sample at Baseline by Treatment Group
Characteristic Controls Statins p Value
Number 6,078 6,078
Enrolment year (%) .797
 1997–2001 34.7 35.5
 2002–2005 25.0 24.9
 2006–2009 18.2 17.9
 2010–2014 22.2 21.7
Demographics
 Age at baseline (y, mean [SD]) 76.4 (9.4) 76.5 (8.9) .555
 Age category (%) .312
  60–79 61.8 62.6
  80+ 38.3 37.4
 Gender (%, women) 45.5 45.5 .956
 Ethnicity (%) .888
  White 82.9 82.7
  Nonwhite 2.1 2.2
  Undisclosed/unreported 15.0 15.1
 Index of multiple deprivations (%) .978
  First quintile (least deprived) 19.7 19.5
  Second 24.3 24.4
  Third 21.2 21.6
  Fourth 20.5 20.0
  Fifth quintile (most deprived) 14.1 14.4
  Undisclosed/unreported 0.20 0.20
Cardiovascular risk factors
 Smoking status (%) .845
  Never 33.1 33.1
  Former 25.4 25.7
  Current 39.2 39.2
  Undetermined 2.3 2.0
 Drinking habit (%) .978
  Never 13.7 13.9
  Current, normal amount 42.2 41.6
  Current, unknown amount 1.0 1.0
  Current, heavy drinker 8.3 8.4
  Former 2.4 2.5
  Undetermined 32.5 32.6
 Body mass index (%) .869
  18.4 or less 1.9 1.7
  18.5–24.9 20.9 20.9
  25–29.9 21.1 20.5
  30 or more 9.6 9.9
  Unmeasured 46.5 47.0
 Total cholesterol level ([in mmol/L], %) .643
  Lower than 6.2 (=240 mg/dL) 27.4 28.2
  6.2 or higher 8.4 8.2
  Unmeasured 64.1 63.6
Health care utilization and measures of disease burden
 Flu vaccination (%) .514
  Received (in the previous year) 48.4 49.4
  Not received (in the previous year) 35.1 34.7
  Never received 16.4 15.9
 Number of drugs (%) .256
  0–1 21.1 20.3
  2–4 19.2 18.3
  5–9 26.9 27.8
  More than 10 32.7 33.6
 Charlson Index (%) .947
  0 30.5 30.2
  1–2 33.4 33.2
  3–4 14.8 15.1
  5 or more 21.3 21.5
 Nursing home visits ([previous year], %) 0.3 0.3 1.000
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Characteristic Controls Statins p Value
 Residential home visits ([previous year], %) 0.4 0.3 .375
 More than 4 GP consultations ([previous year], %) 51.6 52.2 .502
 Any hospitalization ([previous year], %) 15.8 16.2 .553
 Any geriatrics referral ([previous year], %) 0.9 1.1 .311
 Any cardiology referral ([previous year], %) 1.4 1.5 .445
 Revascularization procedures before MI ([non-MI reasons, previous year], %) 0.3 0.3 .862
Diseases at baseline
 Hypertension (%) 40.0 40.7 .437
 Diabetes (%) 5.3 5.7 .248
 Stroke/transient ischemic attack (%) 8.1 8.1 .973
 Congestive heart failure (all stages; %) 43.7 43.8 .869
 Atrial fibrillation (%) 8.5 8.9 .479
 Heart failure (%) 7.7 8.1 .479
 Asthma (%) 11.1 10.6 .414
 Chronic obstructive pulmonary disease (%) 9.1 8.9 .704
 Chronic kidney diseases (stages 3–5; %) 6.5 6.8 .513
 Cancer (%) 9.0 9.2 .614
 Dementia (%) 1.7 1.8 .682
 Depression (%) 14.2 14.7 .470
 Mental health condition (%) 1.2 1.3 .742
 Epilepsy (%) 1.4 1.4 .938
 Hypothyroidism (%) 6.6 6.7 .856
 Incontinence (%) 5.7 5.9 .669
 Osteoporosis (%) 5.3 5.3 .903
 Osteoarthritis (%) 26.3 26.7 .608
 Falls (%) 18.4 18.6 .833
 Fractures (%) 4.7 4.5 .603
 Cirrhosis (%) 0.2 0.3 .563
Drugs at baseline
 Angiotensin-converting enzyme inhibitors (%) 11.3 11.6 .512
 Angiotensin receptors blockers (%) 2.6 3.1 .103
 Renin inhibitors (%) 0.0 0.0 .317
 Calcium channel blockers (%) 6.6 6.9 .406
 Beta-blockers 9.6 10.6 .071
 Alpha-adrenoceptor blocking drugs (%) 2.1 2.2 .573
 Centrally acting antihypertensive drugs (%) 0.2 0.2 .835
 Nonloop diuretics (%) 6.9 7.2 .457
 Potassium-sparring agents (%) 3.0 2.7 .254
 Loop diuretics (%) 16.5 17.2 .265
 Antiplatelets (%) 22.3 23.5 .142
 Oral anticoagulants (%) 2.6 2.9 .315
 Nitrates (%) 9.3 10.1 .133
 Digoxin (%) 3.3 3.5 .726
 Antiarrhythmic drugs (%) 0.9 0.8 .493
 Insulin (%) 1.6 1.5 .770
 Sulphonylureas (%) 2.8 3.1 .286
 Metformin (%) 2.9 3.0 .708
 Other antidiabetic drugs 0.2 0.2 .414
 Corticosteroids (including topical and inhaled; %) 26.6 27.3 .347
 Estrogens (%) 0.9 0.9 .923
 Testosterone (%) 0.0 0.1 .414
 Proton pump inhibitors (%) 16.6 17.8 .071
 H2-receptor antagonists (%) 3.9 4.0 .852
 First-generation antipsychotic drugs (%) 4.8 5.2 .262
 Second-generation antipsychotic drugs (%) 0.5 0.6 .709
 Tricyclic antidepressants (%) 5.2 5.0 .622
 Selective serotonin reuptake inhibitors (%) 4.0 4.5 .209
 Other antidepressants (%) 1.1 1.1 .861
 Anticholinesterase drugs (%) 0.3 0.4 .876
 Cytochrome P450 inhibiting drugs (%) 13.2 13.8 .34
 Anti-Parkinson’s drugs (%) 2.0 2.0 .948
 Drugs for incontinence (%) 3.4 3.7 .303
Notes: GP = general practitioner; MI = myocardial infarction.
Table 1. Continued
246 Journals of Gerontology: MEDICAL SCIENCES, 2017, Vol. 72, No. 2
D
ow
nloaded from
 https://academ
ic.oup.com
/biom
edgerontology/article-abstract/72/2/243/2630000 by Edw
ard Boyle Library user on 10 February 2020
Groups were matched 1:1 using propensity score, based on 60 
of the 73 covariates initially listed (those independently associated 
with exposure and/or primary outcome plus a few variables included 
regardless their lack of association because of their potential con-
founding effect).
End point analyses used survival analysis with competing risk 
models (20), to account for the high frequency of death within this 
age group, and results were reported as subhazard ratio (SHR) and 
95% confidence intervals (95% CI), according to Fine and Gray 
(21). Cox proportional hazard models (using practice ID as strata) 
were used to analyze all-cause mortality and results were displayed 
as HR and 95% CIs.
Data were analyzed by censoring follow-up time of “late users” 
(control group only) when statin prescription was issued according 
to previous research (13). Alternate results obtained without this 
censoring were also presented as Supplementary Material.
Analyses on MI, ST, dementia, and all-cause mortality excluded 
events occurring the first 2 years of follow-up. Exclusion of the first 
2 years of follow-up was based on exploratory analyses (data not 
shown) and meant to (i) reduce “reverse causation” issues (people 
more likely to die in the short period were less likely to be treated 
and patients more likely to have immediate MI recurrence were 
more likely to receive statins), (ii) reduce the confounding effect 
of early nonatherosclerotic coronary events (ie, restenosis or late 
stent thrombosis), and (iii) account for the timing of statin effect on 
cardiovascular outcomes that is likely to be apparent many years 
after treatment initiation (5). The main model for falls and frac-
tures included the first 2 years of follow-up based on considerations 
regarding the shorter timing of statins effects on skeletal muscle. 
Results from alternate models including first 2 years of follow-up 
for MI, ST, dementia, and all-cause mortality, and excluding the first 
2 years of follow-up for falls and fractures were also presented as 
supplementary material.
To investigate the effect of age and burden of disease on out-
comes, using interactions terms, participants were divided into 
age (60–79 and 80+) and disease burden groups. The Charlson 
Comorbidity Index was used to assess disease burden because this 
tool was adapted and validated in the CPRD (22). Patients divided 
into two disease burden groups (Charlson Index: <5, first three quar-
tiles, and ≥5, last quartile (22)). Age and disease burden analyses 
were not data driven but prespecified in the approved protocol, as 
one of the main objects of the present research.
A similar analysis investigated the effect of post-MI revasculari-
zation procedures (percutaneous transluminal coronary angioplasty 
or coronary artery by-pass graft) on the association between statins 
and recurrent MI.
Numbers needed to treat were calculated using a published for-
mula (23).
An alpha level of 0.05 was chosen as the threshold for statistical 
significance for the primary end point and a 0.10 level for inter-
action terms. All secondary end point analyses were considered 
exploratory.
Data were analyzed using the Stata 13 (StataCorp. 2013, Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP).
Results
Sample Characteristics
After propensity score matching, the study sample included 12,156 
people (6,078 per group). Mean age at baseline was 76.5 (SD: 9.2), 
ranging from 60 to 105.4 years, and women comprised 45.5% of 
the sample.
In the treatment group, 78.1% of patients received one statin, 
18.9% two, and the remaining three or four. Of those who received 
one statin, 65% were treated with simvastatin, 28.9% with atorv-
astatin, and the remaining with pravastatin, fluvastatin, or rosuv-
astatin. In the control group, 42.6% of the patients received statin 
treatment ≥57 days after the acute event. Of these “late” statin users, 
29.8% received statins within the first 3 months, 34.5% within the 
first year, and the remaining 36.1% from 1 to 10  years after the 
first MI.
Eighty percent of participants aged 60–79  years and 58% of 
those aged 80+ who were alive for the entire 10-year follow-up 
were still on statins 2 years after the incident MI; these proportions 
decreased to 67.6% and 35.2% at year 4 and to 58.6% and 20.9%, 
respectively, at year 6.
After matching, study groups did not differ for any of the 73 
measured baseline characteristics (Table 1).
Primary End Point
Figure 1 shows SHRs and 95% CI for recurrent MI for the whole 
study sample and by age and disease burden group. Patients were 
followed-up for 43,314 person-years. The rate of MI recurrence was 
19.2 per 1,000 person-years (831 MIs). People treated with statins 
were less likely to have MI recurrence, although the association was 
only marginally significant in the whole sample. Statins showed a 
significant benefit in the 60–79 but not in the 80+ group. Disease 
burden did not affect the estimates.
Number needed to treat for MI recurrence was 154.6 (104.5–
248.2); undergoing revascularization was associated with better 
statin effectiveness (revascularization: SHR = 0.41, 95% CI = 0.27–
0.51, p < .001; no revascularization: 0.95, 0.76–1.19, p = .685; p for 
interaction = .003).
When the first 2 years of follow-up were included in the analysis 
(Supplementary Table S1), statins were associated with a greater MI 
risk, particularly in older people (60–79: 0.99, 0.81–1.21, p = .976; 
80+: 1.46, 1.18–1.81, p < .001; p for interaction = .025).
Secondary End Points
The incidence rate for ST was 7.1 per 1,000 person-years (n = 196 
cases), for dementia was 16.7 (n = 446), for severe falls was 24.8 
(n = 1,026 episodes), for fragility fractures was 7.6 (n = 322), and all-
cause mortality rate was 115.1 (n = 5,165) per 1,000 person-years.
Figure  2 shows SHR and 95% CI for ST, dementia, falls, and 
fractures. No association was found between ST and dementia. 
People treated with statins were at greater risk of severe falls and 
fragility fractures.
The risk of falls (60–79: 1.13, 0.91–1.40, p =  .260; 80+: 1.82, 
1.45–2.30, p < .001; p for interaction = .012) and fractures (60–79: 
1.00, 0.70–1.41, p  =  .993; 80+: 1.91, 1.36–2.67, p < .001; p for 
interaction  =  .019) was greater in people aged 80+ then in their 
younger counterparts.
Although the estimates were not significant, SHRs for ST were 
lower in the 60–79 than in the 80+ group (60–79: 0.73, 0.42–1.14, 
p = .168; 80+: 1.37, 0.81–2.33; p for interaction = .098).
No interaction with age was found for dementia. Burden of dis-
eases did not affect the estimates of ST, dementia, falls, and fractures 
(data not shown).
When events occurring during the first 2 years of follow-up were 
excluded from the analysis, people in the treatment group were less 
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likely to fall than those in the control group (0.73, 0.64–0.85, p < 
.001; Supplementary Table S2).
Participants in the statin group had lower risk for all-cause mor-
tality (HR = 0.62, 0.57–0.68, p < .001). Increasing age (60–79: 0.62, 
0.55–0.72, p < .001; 80+: 0.77, 0.67–0.89, p < .001; p for inter-
action =  .010), but not burden of disease, affected the association 
between statins and all-cause mortality. When follow-up of statin-
treated controls was not censored at the time of statin initiation, the 
benefit of statins on all-cause mortality was substantially attenuated 
(HR = 0.83, 0.78–0.90; p < .001).
Over 10 years, mean total cost per patient in the statin group was 
£24,011 (~$36,000, at exchange rate of $1.50 per £1). For the con-
trol group, the mean total cost was £23,094 (~$34,700). The mean 
cost difference between the groups was £917 (−3,930 to 5,630) 
(~$1,400) per patient. In the 60–79 age group, statins resulted in cost 
savings of −£13,234 (−35,122 to 2,287) (~$20,000) but increased 
costs in the 80+ group £6,729 (5,099–8,265) (~$10,000).
Same associations but lower estimates were found when follow-
up of people taking statins in the control group was not censored 
at the time of statin prescription. Overall mean cost difference was 
−£176 (−2,299 to 1,789) reflecting a cross-over use of statins by 
42% (2,564/6,078) of participants in the control group after the 
start of the observation period. The mean cost difference between 
the groups was £92 per patient. In the 60–79 age group, statins 
resulted in cost savings of −£3,962 (−8,012 to −175) but increased 
costs in the 80+ group £3,377 (1,319 to 5,077).
Discussion
To our knowledge, this is the first study investigating statin effec-
tiveness for the prevention of MI recurrence in a large sample of 
“real-world” older people with incident MI, accounting for a large 
number of covariates and exploring the competing risk of death. 
Results showed that statins were effective in younger old people in 
reducing recurrent MI, with similar effect sizes to those from RCTs. 
In testing for interactions with advanced age, we found evidence of 
more modest protective effects in the older group, but CIs were wide 
and more evidence will be needed to clarify the effect sizes. Burden 
of disease did not affect the estimates. Undergoing post-MI revascu-
larization was associated with greater statin benefit.
Risk of falls and fractures might be higher, particularly in the 
very old during the first years of treatment. No association with ST 
or dementia was found. Finally, people treated with statins were at 
lower risk of all-cause mortality, and yet the benefit was lower in the 
very old. Statin treatment was associated with cost-savings in the 
60–79 but higher costs in the 80+ group.
Data on older people have been provided in RCTs on statins 
including both primary and secondary prevention patients (24–26), 
and results are not easy to directly compare. Overall, our estimates 
for the primary end point (MI) are similar to those of RCTs on 
statins in the age group (60–79) usually enrolled in RCTs (5). To the 
best of our knowledge, only one observational study has evaluated 
the effectiveness of statins on the prevention of MI recurrence in 
“real-world” older patients (9). In this study, conducted in a rela-
tively small sample (n = 1,410) of older patients, the authors found 
that, after adjusting for age, smoking habit, hypertension, diabetes, 
and low- and high-density lipoprotein cholesterol levels, people in 
the statin group were less likely to develop fatal and nonfatal MI 
than people in the control group (relative risk = 0.49, 0.43–0.57) 
(9). Given the limited number of potential confounders included in 
the analysis, the risk of residual confounding, particularly “reverse 
causation,” cannot be excluded in this study.
As expected, statin treatment immediately after MI was probably 
driven by a combination of better short-term prognosis (approxi-
mately fourfold greater first-year mortality rates in controls, data not 
shown) and greater risk of imminent MI recurrence (increased MI 
risk associated with statins when events occurred in the first years 
were included).
The fact that statin benefit might decrease in older age has been 
considered biologically plausible and previously reported in studies 
on statins and mortality (27). Of note, age also markedly affects 
the association between cholesterol levels and mortality for ischemic 
heart disease (28). However, we cannot exclude that the observed 
reduced benefit in people 80+ might result from poor treatment 
persistence.
All secondary end point analyses of this study should be consid-
ered exploratory.
Our results showed that statin was not associated with dementia 
risk. This is in line with a recent Cochrane review (29). The lack of 
association with ST requires consideration. Although not significant, 
Figure 1. Effectiveness of statins for prevention of recurrence of myocardial 
infarction in the whole sample (60+) and by age and disease burden group 
(competing risk of death, excluding first 2 years’ events).
Figure 2. Risk of disabling conditions of older age in the whole sample (60+, 
competing risk of death, excluding first 2 years’ events for ischemic stroke 
and dementia).
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estimates obtained in the 60–79 group are similar to those of RCTs 
and our study was not powered to capture such an effect with small 
number of events.
We found increased risk in falls and fractures, especially in peo-
ple 80+ during the first treatment years. Statins can cause myopathy, 
from subclinical to life-threatening forms, and age and comorbidity 
are important risk factors (30). Its consequences in vulnerable older 
people can potentially be more dangerous than in younger/healthier 
older patients. Although statin use has been associated with lower 
energy and greater muscle exertion (31), longitudinal decrease in 
muscle performance, and increased risk of falls in small studies of 
older people (32), other authors found no association (33) or even 
benefit on skeletal muscle (34). The fact that statins are protective 
from falls after the first 2 years, when follow-up time in statin-pre-
scribed controls was not censored, is not easy to explain. This might 
result from a combination of fall rate reduction in the treatment 
group after the second year of follow-up (discontinuation of treat-
ment in case of adverse reactions and/or timing of muscle damaging 
effect) and concurrent fall rate increase among “late statin users” 
(once they start receiving treatment) in the control group that could 
not be captured when “late statin users” follow-up time was cen-
sured. Alternatively, when taken for longer periods, statins might 
reduce the fall risk by slowing the decline of cardiovascular function.
A number of studies have investigated the association between 
statin use and all-cause mortality (27) in older people with previous 
cardiovascular disease. Our estimates were remarkably consistent 
with those of most published reports (27). The fact that estimates 
of statin benefit for all-cause mortality is greater than that for MI 
recurrence might be explained by long-term noncardiovascular ben-
eficial statin effects such as those on cancer (35); however, we cannot 
exclude the presence of residual confounding.
Previous modeling studies (36) found that statin therapy for sec-
ondary prevention is associated with increased costs to the health 
care system. In contrast, this analysis presents evidence from 10-year 
observational follow-up that statins may result in cost-savings in 
people aged 60–79 years but increased costs in 80+. These results 
warrant further cost-effectiveness analysis that accounts for the 
accrual of health care costs and quantity and quality of life benefits 
to patients.
There are inevitably limitations in the analysis presented. 
Although statin prescription and the main conditions studied are 
likely to be accurately ascertained in the combination of primary 
care and hospital inpatient records used, there may be some under-
diagnosis of dementia and underrecording of falls, but there is no 
apparent reason why these limitations would be associated with sta-
tin receipt after MI. The propensity scoring approach models effects 
only in those cases and controls that have overlapping scores, reduc-
ing the sample size analyzed, although the patients included in analy-
ses are those for whom clinical decisions about adding in statins 
varied after MI in apparently similar cases.
Observational analyses like the one presented here are always 
limited in not being able to definitively exclude the existence of 
residual confounding that might have resulted from unmeasured 
factors, although the very high number of variables used in our pro-
pensity scoring should have minimized such biases. Given that the 
statin-treated group enjoyed lower mortality rates during the up to 
10-year follow-up, the observed associations with injurious falls and 
fractures are unlikely to have been driven by a general excess mor-
bidity in the statins group, but appear to be a specific effect that is 
difficult to explain by residual negative health difference between 
the statin-treated patients and their controls, after matching. The 
main analysis for the primary end point (MI recurrence) excluded 
the first 2  years of follow-up and therefore the results obtained 
cannot be generalizable to the early period of treatment. However, 
because the beneficial effect of statins for cardiovascular prevention 
occurs 1–3 years after treatment start (5), we are confident that this 
exclusion, although helpful to address reverse causation, did not sig-
nificantly bias the primary end point estimates. Finally, a number of 
unmeasured factors might have contributed to the high “noise-to-
signal” ratio reflected by the large variability and CIs in our real-
world older people. Although an “a priori” sample size calculation 
was performed based on the point estimates obtained by Baigent 
and colleagues (5), given the greater proportion of older patients 
in our sample and higher heterogeneity seen in this group, we can-
not exclude that the overall primary end point analysis was slightly 
underpowered.
Along with the limitations, it is worth noting that the analysis 
includes all eligible patients in the data set (ie, the equivalent of a 
100% response rate) and likely negligible loss to follow-up in hos-
pital and death certificate data during our up to 10-year analysis of 
outcomes. The estimates produced are therefore likely to represent 
“real-world” outcomes in typical clinical practice during the period 
studied. Also worth noting is that we have not excluded frail or 
dependent groups including those in nursing and residential homes.
Further work, including RCTs, is needed to replicate these find-
ings in independent populations and to clarify the mechanisms of the 
excess falls and fractures, establishing whether these are driven by 
the well-known effects of statins on muscle or through other mecha-
nisms in older people.
In conclusion, our quasi-experimental analysis of effective-
ness of statins for secondary prevention of MI produced estimates 
in line with results of RCTs for patients aged 60–79  years, but 
more evidence is needed in the older groups. We found evidence 
of excess falls and fractures in very old patients, which deserve 
further investigation. If these results are confirmed, higher falls 
and fracture rates need to be considered in judgments about the 
appropriateness of statin use in older patients. Very old patients in 
our analysis were less likely to stay on treatment for a period long 
enough to provide benefit but long enough to risk serious adverse 
reactions.
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